| | |
|---|
| ASPsiRNA information |
siRNA Id: | aspsirna0905
|
|
siRNA Name: | Sibeta2m02
|
| Mismatch information |
Wild siRNA (As strand 3'->5'): | CUACUCAUACGGACGGCAC
|
|
ASP-siRNA (As strand 3'->5'): | CUACUCAUACGGACGGCAG
|
|
Mismatch position in siRNA: | G1C |
| Gene Information |
Gene Name | Beta 2-microglobulin (B2M) |
|
Target Sequence (5'->3'): | ATTGAAAAAGTGGAGCATTCAGACT
|
|
Wild allele (5'->3'): | GAUGAGUAUGCCUGCCGUG
|
|
Mutant allele (5'->3'): | GAUGAGUAUGCCUGCCGUC
|
|
Position of siRNA on target gene: | 346-364
|
| Respective Gene/Protein Resources |
GenBank Accession: | NM_004048.2 |
| Cytogenic location: | 15q21.1 |
| Chromosomal coordinates: | 15:45,003,684-45,010,356 |
| UniProt ID: | P61769 |
| HUGO ID: | 914 |
|
Reference SNp(RefSNP): | rs10489448 |
| Disease/Mutation information |
Target Mutation: | c.31G>C,p.Ala11Pro
|
|
Matation type/variant: | Single nucleotide variant/Missense variant
|
|
Mutation at gene level: | NG_012920.1:g.5091G>C
|
|
Pathogenic status of mutation: | Pathogenic
|
|
Disease: | HLA incompatibility |
| Clinical Resources |
ClinVar ID: | 17740 |
|
KEGG disease ID: | NA |
|
OMIM ID: | NA |
|
COSMIC: | B2M |
|
DECIPHER: | B2M |
|
GeneTests: | B2M |
| ASP siRNA details |
Mutant allele (5'->3'): | GAUGAGUAUGCCUGCCGUC
|
|
ASP-siRNA (As strand 3'->5'): | CUACUCAUACGGACGGCAG
|
|
Percentage efficacy of ASP-siRNA for mutant allele: | 89
|
|
Wild allele (5'->3'): | GAUGAGUAUGCCUGCCGUG
|
|
ASP-siRNA (As strand 3'->5'): | CUACUCAUACGGACGGCAG
|
|
Percentage efficacy of ASP-siRNA for wild allele: | NA
|
|
Relative difference: | NA
|
| Wild siRNA details |
Wild allele (5'->3'): | GAUGAGUAUGCCUGCCGUG
|
|
Wild siRNA (As strand 3'->5'): | CUACUCAUACGGACGGCAC
|
|
Percentage efficacy of wild siRNA for wild allele: | 50
|
|
Wild allele (5'->3'): | GAUGAGUAUGCCUGCCGUG
|
|
ASP-siRNA (As strand 3'->5'): | CUACUCAUACGGACGGCAG
|
|
Percentage efficacy of Wild sirna for mutant allele: | 90
|
|
Relative difference : | -40
|
| General information |
Mismatch incorporated in siRNA/Target: | siRNA |
| Cell-line used: | Epstein–Barr-virus-immortalized B-lymphocytes |
| Experimental technique used: | Western blot |
| Transfection method: | RNAiFect |
| siRNA expression method: | Ambion |
| Post-transfection duration: | 48 hours |
| Concentration used: | 1.2mIcrog |
| Reference: | 16520945 |
| Delivery method: | Lentiviral vector delivery |
'| Article title: | Class-, gene-, and group-specific HLA silencing by lentiviral shRNA delivery. |
'| Authors: | Figueiredo C, Seltsam A, Blasczyk R. |
'| Journal Reference: | J Mol Med (Berl). 2006 May;84(5):425-37. Epub 2006 Mar 7. |
'
